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Abstract
Introduction This study investigated the effects of a marine
oil extract (PCSO-524®) on inattention, hyperactivity, mood
and cognition in children and adolescents. PCSO-524® is a
standardised lipid extract of the New Zealand green-lipped
mussel and is an inflammatory modulator that inhibits the 5′-
lipoxygenase and cyclooxygenase pathways and decreases
concentrations of the pro-inflammatory arachidonic acid
(AA).
Methods PCSO-524® or a matched placebo was administered
for 14 weeks to 144 participants (123 males/21 females; mean
age 8.7 years) with high hyperactivity and inattention in a
randomised, double-blind, placebo-controlled study. The pri-
mary outcome was the Conners Parent Rating Scale assessing
parental reports of behavioural problems. Secondary outcomes
assessed changes in cognition and mood.
Results The results of the present study did not support the
hypothesis that PCSO-524® improves parental reports of hy-
peractivity, inattention and impulsivity in children ages 6 to
14 years over placebo. Repeated measures ANOVA on post
hoc subsample analysis indicated significant improvements in
hyperactivity (p = 0.04), attention (p = 0.02), learning
(p = 0.05) and probability of ADHD (p = 0.04) with a medi-
um to large average effect size (d = 0.65) in those children
who did not meet criteria for combined hyperactivity and in-
attention. Furthermore, significant improvements in the
PCSO-524® group were indicated in a whole sample repeated
measures ANCOVA on recognition memory between baseline
and week 8 over placebo (p = 0.02, d = 0.56); this difference
was not sustained at week 14.
Conclusions The results presented indicate that PCSO-524®
may be beneficial in reducing levels of hyperactivity and in-
attention in a population of children with clinical and subclin-
ical symptoms of ADHD.
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Introduction
Developmental disorders have detrimental effects on a child’s
social, emotional and academic future (Wehmeier et al. 2010).
Attention-deficit/hyperactivity disorder (ADHD) is the most
prevalent developmental disorder in school-aged children,
with ADHD’s prevalence being estimated withinWestern cul-
tures to be between 5 and 12% (Biederman 2005; Wolraich
et al. 2005). While ADHD is diagnosed by the use of criteria
that establish clinical levels of hyperactivity, impulsivity and
cognitive dysfunction related to inattention and impulsivity
(American Psychiatric Association 2000), subclinical levels
of these symptoms may still be sufficient to cause significant
personal and social distress (Gadit 2003). In fact, subclinical
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ADHD has demonstrated to be a significant risk factor for
alcohol and substance use disorders in later years
(Shankman et al. 2009; Malmberg et al. 2011).
Children who present with ADHD symptoms at the sub-
clinical level highlight an area of child mental health that is
widespread and largely overlooked. Recent research has indi-
cated a prevalence range for this cohort anywhere from 0.8 to
23% of the population (Balázs and Keresztény 2014).
Identifying children with subclinical levels of ADHD may
also aid in the broader understanding of gender differences
in terms of symptom expression and severity (Rielly et al.
2006) as well as aid in the approach to treatment for those
children who are at risk of developing the disorder (Kobor
et al. 2012). As such, there is difficulty for parents to have a
clear understanding of how to approach their child’s behav-
ioural issues and subsequently find appropriate interventions.
Current pharmacological treatments for ADHD can in-
volve the administration of amphetamine-type and methyl-
phenidate substances, which although efficacious are for
many parents an undesirable option. Furthermore, for children
who display milder or subclinical levels of inattention or hy-
peractivity, alternative to amphetamine-type stimulant treat-
ment is arguably preferable. As such, a growing literature
concerning alternative treatments proposed for children and
adolescents with similar behavioural issues to those with
ADHD is developing (Sarris et al. 2011). Although many of
these alternative treatments have not been subjected to rigor-
ous scientific clinical trials, there is growing evidence for
marine-based intervention efficacy in treating behavioural is-
sues associated with ADHD (Sarris et al. 2011).
One increasingly popular treatment for symptoms of
ADHD is supplementation with long-chain polyunsaturated
fatty acid (LC PUFAs). Some researchers have argued that
these LC PUFAs are a viable alternative to methylphenidate
(MPH, e.g. Ritalin®) and other stimulant and non-stimulant
pharmaceutical treatments (Richardson 2006; Sinn and Bryan
2007). Longitudinal research into prenatal development has also
shown that children who have low levels of docosahexaenoic
acid (DHA) in cord blood have increased levels of inattention
and hyperactivity at 10 years of age (Kohlboeck et al. 2011). LC
PUFAsmodifymembrane fluidity, neurotransmitter release, cor-
tical connectivity and organisation, as well as decrease levels of
inflammatory mediators (Hariri et al. 2012). The involvement of
LC PUFAs in processes related to neuronal maturation (Grayson
et al. 2014) further suggests that LC PUFA consumption can
positively influence these molecular processes and that these
changes are also accompanied by behavioural improvements.
A recent clinical trial involving 40 boys with ADHD and
39 healthy controls compared the effect of 16-week adminis-
tration of combined eicosapentaenoic acid (EPA)/DHA
against placebo on behaviour and cognition (Bos et al.
2015). Significant improvements due to the treatment were
observed for both the ADHD and control groups due to the
EPA/DHA treatment on parent-rated inattention scores but not
on the more objectively assessed cognitive processes (Bos
et al. 2015). Research findings in this area have been some-
what mixed with several positive findings for LC PUFAs on
behavioural outcomes in children and adolescents, as well as
several failures to replicate (Sarris et al. 2011). Nevertheless, it
should be noted that two recent meta-analyses have suggested
positive but small effect sizes for LC PUFAs and behavioural
symptoms with children and adolescents with ADHD
(Sonuga-Barke et al. 2013; Bloch and Qawasmi 2011). One
particular problem in understanding whether omega-3 supple-
ments are efficacious in children with high hyperactivity, in-
attention and impulsivity is the lack of clarity with regards to
the mechanism of action. One promising marine-based prep-
aration that may benefit children and adolescents with behav-
ioural problems and which is rich in LC PUFAs is PCSO-
524®, which contains a standardised lipid extract of the
New Zealand green-lipped mussel (Perna canaliculus). The
extract contains a unique combination of free fatty acids, sterol
esters, polar lipids and carotenoids that provide a highly con-
densed form of marine lipids (Kalafatis 1996). Experimental
studies demonstrate that the PCSO-524® extract is effective at
modulating 5′-lipoxygenase (5-LOX), 12′-lipoxygenase (12-
LOX) and cyclooxygenase (COX) pathways, which are re-
sponsible for the production of eicosanoids, which include
leukotrienes and prostaglandins (Halpern 2000; Whitehouse
et al. 1997; Whitehouse and Rainsford 2006). PCSO-524®
also elicits an anti-allergic and anti-inflammatory action by
controlling the 5-LOX pathway. This regulates both the in-
flammatory and immune responses, specifically the allergic
response induced by interleukin-4 (IL-4) (Dugas 2000). The
safety and efficacy of the extract PCSO-524® have been ex-
amined in adult, child and adolescent populations, with posi-
tive effects in terms of reduced asthmatic (Lello et al. 2012;
Emelyanov et al. 2002; Mickleborough et al. 2013), inflam-
matory bowel disease (Tenikoff et al. 2005) and osteoarthritis
symptoms (Zawadzki et al. 2013). With respect to the poten-
tial application for symptoms of inattention, impulsivity or
hyperactivity, the anti-inflammatory actions of PCSO-524®
may benefit children who have clinical or subclinical ADHD
by decreasing the ratio of arachidonic acid (pro-inflammatory)
to eicosapentaenoic acid (anti-inflammatory) (AA/EPA),
which may lead to improvements in associated symptoms
(Young et al. 2005; Sorgi et al. 2007).
In the current randomised controlled trial, we investigated
the effects of PCSO-524® on the symptoms of hyperactivity,
impulsivity, inattention and cognition. The primary aim of the
current study was to determine if supplementation with
PCSO-524® reduced parental reports of hyperactivity and
inattention in a population of Australian children and adoles-
cents aged 6 to 14who had increased levels of hyperactivity or
inattention compared with placebo. A secondary aim of the
study was to investigate changes in objective computerised
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measures of cognition and mood as well as electrophysiolog-
ical measures of brain wave ratios.
Methods
Overview
The study was a 14-week randomised, double-blind, place-
bo-controlled, two-arm, parallel group clinical trial for
which children and adolescents were randomised to receive
either three capsules (≤45 kg) or four capsules (>45 kg) of
PCSO-524® or a matching placebo. This study was ap-
proved by the Swinburne University Human Research
Ethics Committee (project 2010/175) and was registered
with the Australian New Zealand Clinical Trials Registry
(ANZCTRN12610000978066). All procedures were con-
ducted in accordance with the Declaration of World
Medical Association (2008) and good clinical practice
(GCP) guidelines. For an expanded discussion on the
methods for this study, see Kean et al. (2013).
Study aims and hypotheses
The primary aim of the study was to examine the effect of
14 weeks of administration of PCSO-524® on levels of hy-
peractivity, impulsivity and inattention in children aged 6 to
14 years compared with placebo. The primary outcome was
the Conners Parent Rating Scales (CPRS), a comprehensive
checklist for acquiring parental reports of the behavioural
problems that presented, which was completed every 4 weeks
(Conners et al. 1998). Secondary outcomes investigated cog-
nitive changes by the use of the Test of Variables of Attention
(TOVA; Greenberg and Waldman 1993) and the Computerised
Mental Performance Assessment System (COMPASS; Scholey
et al. 2010). Changes in mood were assessed by the use of the
Brunel Mood Scale (BRUMS) for adolescents (Terry et al.
1999). These mood scales were completed by the parents inde-
pendently or (more usually) with the child. The acquisition of
resting-state electroencephalography (EEG) was based on pre-
vious research into the differentiation of theta/beta and theta/
alpha ratios from non-ADHD children (Mann et al. 1992) as
well as between subtypes (Clarke et al. 2001). This was con-
ducted in two states: eyes open and eyes closed. For the sake of
brevity, the EEG results are reported elsewhere.
Participants and trial site
One hundred and forty-four children aged between 6 and
14 years were recruited for the study and initially allocated
to either a PCSO-524® or placebo group. All cognitive and
electrophysiological testing took place within the Swinburne
Centre for Human Psychopharmacology at Swinburne
University, in Victoria, Australia. Parents completed addi-
tional CPRS forms at home during weeks 4, 10 and 18
(4 weeks post-treatment). Families that were based inter-
state (distant participants) completed all CPRS, BRUMS
and symptom checklists in their home environments, at
scheduled time points.
Inclusion criteria
Inclusion criteria were as follows: healthy, non-smoking
males and females aged between 6 and 14 years, who had
Diagnostic and Statistical Manual of Mental Disorders
Fourth Edition (DSM-IV) ADHD rating score of greater than
15, who were fluent in English, had parental or legal guardian
consent and verbal consent from the child. The DSM-IVrating
scale is a reliable and valid four-point (0 = never or rarely,
1 = sometimes, 2 = often, 3 = very often) 18-item semi-struc-
tured interview that assesses symptom severity (Faries et al.
2001). A score of 15 points or higher on the DSM-IV
rating scale allowed investigators to establish that partic-
ipants had elevated levels of hyperactivity, inattention or
both. Criteria for ADHD subtypes (inattentive or hyperac-
tive-impulsive), requires six or more scores in the higher
range (2 = often, 3 = very often) of the scale for that
subtypes (DuPaul et al. 1998).
Exclusion criteria
Exclusion criteria were as follows: primary medical diagnosis
other than ADHD, oppositional defiant disorder or similar
behavioural disorders; currently taking any medication (other
than stimulants if a formal diagnosis of ADHD or other be-
havioural disorder has been made); current or history of heart
disease, or high blood pressure, or diabetes; health conditions
that would affect food metabolism, including the following:
food allergies, kidney disease, liver disease and/or gastrointes-
tinal diseases (e.g. irritable bowel syndrome, coeliac disease,
peptic ulcers); pregnant or breast feeding; unable to participate
in all scheduled visits, treatment plan, tests and other trial
procedures according to the protocol; allergy to shellfish; ep-
ilepsy or photosensitivity.
Intervention
The active trial treatment was the naturally occurring
omega-3 anti-inflammatory extract PCSO-524®. The lipid
extract PCSO-524® of the New Zealand green-lipped mus-
sel is marketed under the brand names Lyprinol® and
Omega XL®. The principal ingredients per 260 mg capsule
for the active capsules include PCSO-524® GLM pat.
lipids (eicosatetraenoic acid)—50 mg (including EPA
7.3 mg and DHA 5.5 mg, natural mono-unsaturated olive
oil 100 mg and vitamin E (D-alpha-tocepherol) as an
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antioxidant 0.225 mg). PCSO-524® also includes sterol
esters that consist of mainly myristic acid, palmitic acid,
palmitoleic acid, stearic acid, oleic acid and linoleic acid.
The sterols found in this fraction included cholesterol,
cholesta-3,5-diene, 26,27-dinoergostadienol, cholesta-
5,22-dien-3-ol and ergosta-5,22-dien-3-ol. The placebo
capsule contained 35.5 mg of olive oil, 112 mg of lecithin,
12 mg of coconut oil and 0.5 mg of 30% beta-carotene.
Both treatments were contained within capsules that
consisted of gelatin, sorbitol syrup and glycerin. The place-
bo capsule matched the PCSO-524® capsule in touch, taste,
smell and size.
Randomisation and treatment schedule
Participants were allocated randomly to coded treatment
groups. All participants were assigned to treatment groups A
or B through the use of a computer-generated random number,
which was done by a neutral third party. Blinding was
achieved by enlisting a person outside of the project to code
the treatments and maintain the key to this code until data
collection was completed. An emergency code break envelope
was provided to the principal investigator, which was to be
opened only in case of emergency. The schedule for testing is
presented in Table 1. Weight plays a large role in the digestion
and absorption of nutrients, so weight was used to determine
how many capsules each child would be required to consume
(≤45 kg = 3 capsules; >45 kg = 4 capsules).
Procedure
Parents who were interested on behalf of their children
contacted the university via telephone or e-mail and
underwent a telephone screen to determine the eligibility of
their child. Eligible participants who lived interstate were pro-
vided with hard copies of consent forms and were enrolled in
the study after signed hard copy consent forms had been
returned. Eligible children attended the university and com-
pleted consent on-site on the practice day. All families
underwent a practice day information session or telephone call
during which they completed screening questionnaires and
familiarised themselves with the study procedures and tests.
Local (on-site) participants underwent a baseline session dur-
ing which they completed all tests (which included an EEG)
and were allocated randomly to receive one of the two treat-
ments (PCSO-524®/placebo). They were required to take ei-
ther three or four capsules daily (in the morning, with break-
fast) for 14 weeks. The outcome measures, including the pri-
mary outcome, the CPRS, were completed by parents during
weeks 2 (baseline), 4, 8, 10, 14 and 18 (Conners et al. 1998).
Families that lived interstate were mailed a study kit that
contained the participant’s randomised treatment and were
contacted to complete their study forms on specific dates, after
their baseline start date. These participants did not complete
cognitive assessments. Remaining testing sessions followed
the schedule detailed in Table 1. Participants completed a
treatment compliance diary and marked each day when their
child consumed their treatment.
Table 1 Study outline
V1 V2 V3 V4
W1 W2 W4 W8 W10 W14 W18
On-site participants Prac Swin AH Swin AH Swin F/Up
Distant participants Prac AH AH AH AH AH AH
Behavioural and demographic measures
Structured interview (DSM ADHD rating) X
Connors Parent Rating Scale X X X X X X
Global Clinical Impression scalea X X X
Current health and medical questionnaire X X X X X X
Demographics questionnaire X
Omega-3 intake/food diary X X
Cognitive and psychophysiological measures
COMPASS cognitive batterya X X X X
Test of Variables of Attention (TOVA)a X X X X
Brunel Mood Scale (BRUMS) X X X X X X X
EEG resting statea X X X
Steady-state topography (CPT-AXE)a X X X
a These items were not completed by inter-state participants
AH at home, Swin at Swinburne, Prac practice day, CPT-AXE continuous performance task-AXE
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At the end of the study, participants were required to return
the compliance diary as well as any remaining treatment. A
follow-up telephone call was undertaken at the conclusion of
the study to enquire about compliance rates for each partici-
pant. All parents completed a food frequency questionnaire on
behalf of the child at the start of the study and then a subse-
quent 7-day food diary during week 4 to determine if the
child’s omega-3 intake from non-trial sources remained con-
sistent throughout the trial. Parents also completed the CPRS
and the BRUMS 4 weeks following the cessation of the active
or placebo administration (week 18) to determine if there were
any changes inmood or behaviour. Parents completed a symp-
tom checklist to monitor for any adverse events. Parents were
questioned about any non-specific adverse events (AEs) at
each scheduled time point (weeks 4, 8, 10, 14 and 18).
Outcome measures
The a priori primary outcome was the CPRS (Conners et al.
1998). Secondary outcomes included the computerised
COMPASS cognitive battery, designed to allow assessment
across the major cognitive domains, i.e. attention, working
memory, secondary memory and executive function
(Scholey et al. 2010). The following cognitive COMPASS
tasks were administered: word presentation, immediate word
recall, picture presentation, simple reaction time, choice reac-
tion time, numeric working memory, delayed word recall,
delayed word recognition and delayed picture recognition.
Each outcome was scored in terms of accuracy and speed of
response. The TOVA was employed to objectively assess
symptoms of inattention and impulsivity. The TOVA is a
computer-based assessment of inattention (Greenberg and
Waldman 1993). It is considered to be a gold standard test
for ADHD and associated symptoms (Llorente et al. 2008).
The test has two modes divided into four quarters. The target
infrequent mode in quarters 1 and 2 (36 targets; 126 non-
targets) is the traditional form used to measure vigilance.
This is followed by the target frequent mode in quarters 3
and 4 (126 targets; 36 non-targets) that denoted the high inhi-
bition demand mode. The BRUMS, known formerly as the
Profile of Mood States-Adolescents (POMS-A), was used to
assess the mood states of the children. The BRUMS
contained 24 simple mood descriptors such as angry, ener-
getic, nervous and unhappy. It was designed specifically for
adolescent populations, and the validation process can be
found in Terry et al. (1999).
The Global Clinical Impression (GCI) scale was used to
measure illness severity, global improvement or change and
therapeutic response. The GCI is rated on a seven-point scale,
with the severity of illness scale using a range of responses
from one (normal) through to seven (among the most severely
ill patients (Busner and Targum 2007)). Parents also complet-
ed a Food Frequency Questionnaire (FFQ) that provided a
detailed description of the child’s food intake. During week
4 of the trial, parents completed a 7-day food diary that re-
corded what the child ate for breakfast, lunch and dinner, as
well as any significant snacks throughout those days. This
diary was compared with the FFQ at baseline to determine
any changes in diet that may have occurred during the study.
Resting EEG and steady-state topography (SST) were record-
ed in on-site participants; however, the results due to their size
are not reported here.
Statistical analysis
Analysis was performed using the Statistical Package for the
Social Sciences (SPSS v.20). Repeated measures analysis of
variance (ANOVA) were applied to all data, and in each anal-
ysis, diagnosis and medication were included as categorical
covariates. Analysis of covariance (ANCOVA) was applied to
all cognitive data to control for any confounding variables that
may have impacted the performance on the measures. A mul-
tiple comparison test (Bonferroni) was applied to all data,
which included all exploratory subsample analyses and the
effect sizes (Cohen’s d) provided. Cohen’s effect sizes are
interpreted as 0.2 = small, 0.5 = medium and 0.8 = a large
effect size. Significance level was set at a p < 0.05. Intention-
to-treat analysis, which used the last observation carried for-
ward, was applied to any missing data from endpoint analysis,




Three hundred and fifty-one participants were screened ini-
tially for the trial, which resulted in 144 participants who met
inclusion criteria and who were randomised to receive either
PCSO-524® or a placebo for 14 weeks. The mean age was
8.7 years (SD = 2.24) of whom 123 were male and 21 were
female (see Table 2 for demographic data). In total, the data of
112 participants were included for final analysis through the
use of intention-to-treat analysis, with the final observation
carried forward. Following random assignment and dropouts,
there was a significant demographic difference in the number
of females in the PCSO-524® group compared to the placebo
group (N = 17; PCSO-524® n = 14). To further explore this, a
repeated measure analysis was conducted investigating the
effect of treatment on male and females only. This data is
reported further on.
Whole sample treatment group differences were noted in
secondary outcome, the COMPASS cognitive task, which in-
cluded significant improvements in working memory on three
domains in favour of PCSO-524®. No further treatment group
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differences were found in an analysis of the entire sample on
remaining primary and secondary outcomes.
As the sample population included children taking pharma-
ceutical medications, careful interpretation of the analysis and
outcomes was needed. Each result was analysed using diag-
nosis and medication status as a covariate. Any statistical in-
fluence of these covariates on any outcome is noted in the
relevant analysis. These participant numbers are broken down
by groups including on-site testing, distant testing and gender
as well as to which treatment group these participants were
randomised (see Table 3 and Fig. 1).
ADHD assessment scales
Conners Parent Rating Scale
A baseline summary of the CPRS data was included investi-
gating differences between demographic data (see Table 4).
Comparisons between gender, medication status, diagnosis
status and testing location were conducted using paired sam-
ple t test. Any significant outcome was further investigated
using Wilcoxon signed-rank test for non-parametric datasets.
There were significant baseline differences for the peer rela-
tions (p < 0.05), oppositional defiant disorder (p < 0.01), im-
paired relationships (p < 0.01) and impaired home life
(p < 0.01) outcomes between the diagnosed and non-
diagnosed groups as well as significant differences on the peer
relations (p < 0.05) and impaired relationships (p < 0.05) be-
tween medicated and non-medicated groups. No further differ-
ences were noted in any other demographic data at baseline.
Despite these demographic differences, following randomisation,
there were no significant differences between treatment groups
on any of the CPRS outcomes.
Analysis of the primary outcome found no significant dif-
ferences between treatment groups on CPRS following 14-
week supplementation. To further understand potential treat-
ment effects, we also conducted post hoc analyses with sub-
groups. This was done to better understand whether there was
a treatment effect related to the severity of the symptoms
displayed by children and adolescents. Subsample analysis
indicated significant treatment effects for participants who
had less-severe symptoms (high inattention, high hyperactiv-
ity or no subtype—non-combined type) than those who had
more severe symptoms (combined high hyperactivity and in-
attention—combined type) based on attention-deficit/hyper-
activity disorder IV rating scale scores (DuPaul et al. 1998).
Non-combined type (NCT) (N = 43; PCSO-524® n = 23)
analysis revealed a significant improvement in children who
consumed PCSO-524® on CPRS scores of hyperactivity,
learning abilities and improved behaviour at home, as well
as improvements on DSM scores of attention and hyperactiv-
ity. Furthermore, there was a significant reduction in ADHD
probability ratings in children who consumed PSCO-524®
compared with placebo; this result was associated with a main
effect for diagnosis (p = 0.03) (see Table 5). No baseline
differences were seen in the NCT sample. There were also
no significant differences between treatment groups in terms
of those with high inattention (p = 0.08) or high hyperactivity
(p = 0.10) at baseline. The NCT subsample was comprised of
three classifications, which included those whomet criteria for
high inattention, those who met criteria for high hyperactivity
and those who did not meet criteria for either high inattention
or high hyperactivity, denoted from here as non-subtype
group. Further analysis of these groups found that those chil-
dren taking PCSO-524® and displaying high inattention
(N = 19; PCSO-524® n = 11) improved in parental ratings
of executive function (p = 0.01; d = 0.38), aggression
(p = 0.01; d = 0.70), conduct (p < 0.01; d = 1.03) and oppo-
sitional defiance (p = 0.04; d = 0.46). Improvements in
aggression and oppositional defiance were associated
with main effects for medication (p < 0.05) and diag-
nosis (p < 0.05). This may indicate the potential for
PCSO-524® as an adjunct therapy in ADHD-diagnosed
children displaying specific issues with attention; how-
ever, future studies are needed to establish this associa-
tion. Improvements in executive function were also as-
sociated with a main effect for diagnosis (p < 0.05).
There were no improvements on any domain for those
children displaying symptoms of high hyperactivity
(N = 10; PCSO-524® n = 4) or the non-subtype group
(N = 15, PCSO-524® n = 9). Only a single baseline
difference was noted in the conduct issues outcome for
the non-subtype group (p < 0.05).
Group analysis of the combined type (CT) (N = 65; PCSO-
524® n = 29) revealed an improvement in attention, executive
function and DSM ratings of attention in the placebo group
(see Table 6); however, both symptoms of executive function
and DSM ratings of attention showed a significant main effect
for medication status, which highlights the possible influence
of pharmaceutical treatment on parental ratings of partici-
pant’s behaviour. No baseline differences were noted in the
CT sample.
Table 2 Demographic characteristics of study participants (N = 112)
Mean SD Min Max
Age yrs 8.82 2.27 6 14
Height cm 138.45 14.64 100 172
Weight kg 35.75 13.8 19 90
Education yrs 4.65 2.35 1 10
Handedness n (%) R 99 (88.4%)
L 11 (9.8%)
L/R 2 (1.7%)
yrs years, n number, cm centimetre, kg kilogram, R right handed, L left
handed, L/R left and right handed
408 Psychopharmacology (2017) 234:403–420
Clinical Global Impression scale
There were no significant differences between treatment
groups at baseline or during the following 14 weeks of
treatment.
Cognitive assessment
Computerised Mental Performance Assessment System
There were no significant differences between groups at base-
line for any of the cognitive measures. Results of the reaction
time cognitive data did not include fast guesses (<200 ms).
Whole sample analysis (N = 85) revealed significant effects in
favour of PCSO-524® between baseline and week 8.
ANCOVA analysis was conducted using diagnosed and med-
ication status as well as baseline scores as covariates. The
main outcomes were improved memory accuracy scores of
participants in the PCSO-524® group when they recalled tar-
get (p = 0.05, d = 0.48) and non-target (p = 0.02, d = 0.56)
pictures correctly; this is complemented by significant overall
picture recognition accuracy (p = 0.02, d = 0.56) (see Fig. 2a–
c). There were no main effects for diagnosis or medication on
any of the whole sample outcomes.
COMPASS subsample analysis
Baseline differences (p < 0.05) were noted between treatment
groups on three subscores for the word recognition task in the
diagnosed (Ds) (n = 28; PCSO-524® n = 14) subsample only. A
single significant differencewas noted on the delayedword recall
task in the non-diagnosed (NDs) (n = 57; PCSO-524® n = 31)
subsample (p < 0.05). No other baseline differences were noted
in either subsample. Therewere nomain effects formedication in
the diagnosed subsample on any COMPASS outcome.
In the NDs subsample, significant improvements were seen
on the same working memory scores as in the whole sample
analysis. ANCOVA analysis of the subsample revealed that
those in the PCSO-524® group had improved picture recog-
nition (p = 0.03, d = 0.67), correct target picture recognition
(p = 0.05, d = 0.58) and correct non-target picture recognition
(p = 0.02, d = 0.69). In the Ds subsample, a significant im-
provement in numeric working memory (Fig. 3) was demon-
strated in those taking PCSO-524® between baseline and
week 8 (p = 0.02, d = 0.92).
Test of Variables of Attention
The TOVA is a highly demanding task that requires significant
sustained attention during a long period of time. Analysis was
conducted using a 2 × 2 repeated measures ANOVA
(quarter × time) on each mode (target-infrequent [first
half] mode or target-frequent [second half]) mode to eval-
uate the individual influences of each quarter on the data.
Any quarter that had excessive omission errors (>90%)
was considered invalid. Participants whose data was
deemed invalid were removed from the final analysis.
Seventy-seven participant datasets were included in the
final analysis. There were no significant differences be-
tween groups at baseline. No statistically significant dif-
ferences were found between the treatment groups in
whole sample analysis.
TOVA subsample analysis
In the NDs subsample (n = 52; PCSO-524® n = 28), the
PCSO-524® group showed significantly increased speed
when they gave a correct response to a target following an
error (post-commission) and demonstrated sustained consis-
tency of those responses compared with placebo over the
Table 3 Full sample demographics broken down by location, sex, diagnosis and medication
Overall (N = 144) Total distant participants (N = 41) Total on-site participants (N = 103) Final sample (on-site) (N = 112)
PCSO-524® Placebo PCSO-524® Placebo PCSO-524® Placebo PCSO-524® (45) Placebo (41)
Male 57 66 12 24 44 43 40 55
Female 17 4 4 1 13 3 14a 3
Diagnosis 36 37 8 18 28 19 22 28
Medicationb 23 29 7 14 16 15 13 22
Ritalin LA (mg) SA (mg) 4 (20) 0 (0) 2 (30) 5 (9)
Concerta LA (mg) SA (mg) 7 (36) 0 (0) 9 (35) 0 (0)
Dexam LA (mg) SA (mg) 1 (12.5) 0 (0) 0 (0) 2 (10)
Strattera LA (mg) SA (mg) 1 (40) 0 (0) 2 (32) 0 (0)
Dexam dexamphetamine, LA long acting, mg average milligram per dose of that specific medication, SA short acting
a There was a significant difference in the number of females between treatment groups
b Eight participants failed to provide dosage (mg) information (PCSO-524® n = 2); two could not provide medication type (PCSO-524® n = 0)
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14 weeks during the target-infrequent mode (see Table 7). In
the target-frequent mode, those in the placebo group made
significantly more multiple responses than those in the
PCSO-524® group (see Table 8). This demonstrated an
example of improved inhibitory mechanisms. For the Ds
sample (n = 25; PCSO-524® n = 12), those in the PCSO-
524® group showed slower reaction times when they
responded to target stimuli (p = 0.09, d = 0.18), which
Inter-state families failed to return data
Undisclosed co-morbid disorders at recruitment 
stage 
Intenon to Treat analysis n=4 (PCSO-524® n=1)
Inter-state:     17 
Local:               41 
Inter-state:     9 
Local:               45 
Phone Screen 
351 




Lost to follow up / 
no longer interested 
85 












Lost to follow up n=10 
(PCSO-524® n=5)  







Intenon to Treat 
(n=4) Total  
112 
Fig. 1 Flowchart of study
protocol
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was complemented by another trend, which demonstrated
that those children who consumed PCSO-524® made
fewer errors than the placebo group over 14 weeks
(p = 0.08, d = 0.20).
Table 5 Non-combined-type CPRS scores
Non-combined type
PCSO-524 (n = 23) Placebo (n = 20)
Variables n Baseline Week 14 Baseline Week 14 p valuea Cohens d
Inattention 43 74.57 ± 12.17 61.61 ± 12.45 74.10 ± 11.49 67.55 ± 12.14 0.11 0.48
Hyperactivity 43 73.04 ± 14.52 62.87 ± 14.24 75.00 ± 13.58 71.70 ± 13.08 0.04 0.64
Learning problems 43 63.48 ± 17.69 57.61 ± 12.88 68.90 ± 12.62 66.15 ± 14.79 0.05 0.62
Executive function 43 65.30 ± 13.29 57.09 ± 11.81 65.45 ± 12.64 63.20 ± 11.29 0.09 0.53
Aggression 43 72.96 ± 16.56 65.78 ± 17.73 68.75 ± 15.05 69.20 ± 15.50 0.49c 0.20
Peer relations 43 64.87 ± 15.94 61.65 ± 18.24 64.45 ± 18.73 60.80 ± 14.23 0.85c 0.05
DSM inattention 43 71.83 ± 12.58 58.00 ± 11.84 70.80 ± 12.56 66.75±13.10 0.02 0.70
DSM hyperactivity 43 71.04 ± 13.86 62.39 ± 12.54 72.30 ± 12.63 70.00 ± 11.81 0.04 0.62
Conduct disorder 43 65.39 ± 14.68 56.83 ± 14.32 64.00 ± 13.61 63.90 ± 15.58 0.12 0.47
Oppositional defiant disorder 43 68.00 ± 13.76 62.00 ± 14.54 66.90 ± 12.98 62.50 ± 10.45 0.89 0.04
Global ADHD index 43 73.87 ± 11.97 63.13 ± 11.86 73.05 ± 11.50 68.35 ± 11.36 0.14c 0.45
Impaired school life 43 1.83 ± 0.89 1.26 ± 1.01 2.05 ± 1.00 1.75 ± 1.07 0.13 0.47
Impaired relationships 43 1.09 ± 1.00 1.09 ± 1.08 1.30 ± 0.98 1.35 ± 0.88 0.41b 0.27
Impaired home life 43 1.39 ± 0.99 0.87 ± 1.01 1.50 ± 1.15 1.55 ± 0.83 0.02 0.73
ADHD probability 43 79.61 ± 24.93 51.30 ± 28.44 81.75 ± 18.36 68.70 ± 29.82 0.04c 0.60
a Significant values—Bonferroni multiple comparison test
b Outcome was associated with a main effect for medication
c Outcome was associated with a main effect for diagnosis
Table 4 Baseline scores for Conners Parent Rating Scale based on demographic data (N = 112)
Sex Medicated Diagnosed On-site
Male Female YES No Yes No Yes No
Inattention 78.84 ± 11.09 83.25 ± 10.21 81.25 ± 8.79 79.33 ± 11.65 81.27 ± 8.84 78.92 ± 12.10 80.50 ± 10.84 78.00 ± 10.97
Hyperactivity 80.85 ± 12.25 80.75 ± 15.34 85.09 ± 7.64 80.07 ± 13.37 84.49 ± 9.26 79.46 ± 13.53 82.20 ± 12.48 79.54 ± 11.03
Learning problems 68.66 ± 14.87 73.00 ± 16.28 73.69 ± 13.14 67.50 ± 15.20 70.47 ± 14.45 68.52 ± 15.16 69.33 ± 15.49 69.35 ± 12.79
Executive function 69.12 ± 11.76 74.38 ± 16.61 71.56 ± 10.80 70.64 ± 13.38 71.56 ± 11.76 70.46 ± 13.29 71.70 ± 13.04 68.46 ± 11.10
Aggression 77.36 ± 14.67 69.88 ± 17.98 79.41 ± 12.86 75.78 ± 15.71 79.69 ± 13.17 74.83 ± 15.91 76.66 ± 15.33 77.46 ± 13.98
Peer relations 70.78 ± 16.78 63.38 ± 22.36 78.81 ± 15.10 67.75 ± 17.16 77.44 ± 15.36 66.44 ± 17.21 71.01 ± 17.41 71.08 ± 17.16
DSM inattention 75.45 ± 10.74 79.50 ± 14.16 77.25 ± 9.25 76.74 ± 11.97 77.24 ± 9.72 76.63 ± 12.20 77.70 ± 11.27 74.35 ± 10.75
DSM hyperactivity 79.14 ± 12.38 78.75 ± 15.56 83.31 ± 8.93 78.37 ± 13.29 82.78 ± 10.38 77.73 ± 13.23 80.78 ± 12.54 76.85 ± 11.37
Conduct disorder 70.07 ± 15.61 70.00 ± 16.41 73.06 ± 15.10 69.57 ± 15.86 73.29 ± 15.07 68.68 ± 15.89 70.70 ± 15.83 70.31 ± 15.37
Oppositional defiant
disorder
75.88 ± 12.81 66.00 ± 17.62 79.16 ± 10.98 73.64 ± 13.95 79.24 ± 11.27 72.44 ± 14.04 75.02 ± 13.76 76.08 ± 12.09
Global ADHD index 79.88 ± 11.52 80.38 ± 11.70 84.53 ± 7.26 78.82 ± 12.21 84.04 ± 7.48 77.98 ± 12.78 80.85 ± 11.57 79.42 ± 10.34
Impaired school life 2.21 ± 0.93 2.25 ± 0.89 2.28 ± 0.92 2.20 ± 0.91 2.24 ± 0.96 2.21 ± 0.88 2.24 ± 0.90 2.15 ± 0.97
Impaired relationships 1.70 ± 0.98 1.00 ± 1.41 1.97 ± 1.03 1.51 ± 1.04 2.00 ± 1.00 1.40 ± 1.02 1.67 ± 1.02 1.58 ± 1.17
Impaired home life 1.99 ± 0.96 1.38 ± 1.19 2.31 ± 0.86 1.80 ± 1.03 2.33 ± 0.83 1.68 ± 1.04 1.98 ± 1.03 1.88 ± 0.95
ADHD probability 88.01 ± 20.74 87.50 ± 15.75 94.75 ± 8.26 86.41 ± 22.43 93.67 ± 14.53 85.46 ± 22.13 88.98 ± 19.73 88.58 ± 19.89
Significant differences are in bold
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Mood assessment
Brunel Mood Scales (BRUMS)
The data of 108 participants were used for analysis. There
were no significant differences between treatment groups at
baseline. Whole sample analysis revealed significant changes
in feelings of fatigue and confusion. Fatigue increased in the
PCSO-524® group until week 8 (p = 0.02, d = 0.49), when it
levelled off at week 14 (p = 0.01, d = 0.53), whereas there was
a consistent decrease in fatigue in those children in the placebo
group. Both treatment groups had reduced feelings of confu-
sion during the 14 weeks; however, the placebo group did so
more significantly at week 8 (p = 0.02, d = 0.46) and at week
14 (p = 0.01, d = 0.55).
BRUMS subsample analysis
In the Ds subsample, there was a significant decrease in feel-
ings of confusion in the placebo group at week 8 (p = 0.00,
d = 1.14) and at week 14 (p = 0.03, d = 0.68). Subsample
analysis of the NDs subsample demonstrated a significant
reduction in feelings of fatigue in the placebo group between
baseline and week 14 (p = 0.02, d = 0.63), compared with
PCSO-524®. This was accompanied by a trend in decreased
feelings of depression (p = 0.07, d = 0.48) and confusion
(p = 0.07, d = 0.47) in both treatment groups, with greater
significance in the placebo group.
Sex differences
To evaluate the difference between gender on behavioural
outcomes, a repeated measure ANOVA was conducted on
males in the study. An analysis on females was not conducted
due to the low number of females at the conclusion of the
study coupled with the difference in numbers between groups.
A repeated measures ANOVA using Bonferroni multiple
comparison analysis was conducted on the male-only cohort.
There were no significant differences between treatment
groups on any CPRS domains following a whole sample anal-
ysis (N = 91; PCSO-524® n = 38) or for a CTanalysis (N = 56;
PCSO-524® n = 21). In an NCT analysis of males only
(N = 35; PCSO-524® n = 17), there were significant improve-
ments in CPRS ratings of attention (p = 0.03, d = 0.74), hy-
peractivity (p = 0.00, d = 1.13), learning problems (p = 0.03,
d = 0.78), as well as DSM ratings of attention (p = 0.02,
d = 0.80) and hyperactivity (p = 0.00, d = 1.09). There were
further improvements on the global index of ADHD (p = 0.01,
d = 0.86) and ratings of impaired home life (p = 0.01,
d = 0.82), as well as improved ADHD probability ratings
(p = 0.00, d = 0.91). The CPRS ratings of attention and the
Table 6 Combined-type CPRS scores
Combined type
PCSO-524 (n = 29) Placebo (n = 36)
Variables n Baseline Week 14 Baseline Week 14 p valuea Cohens d
Inattention 65 83.59 ± 9.19 77.34 ± 13.23 83.56 ± 8.14 71.03 ± 13.61 0.04 0.47
Hyperactivity 65 87.03 ± 6.34 78.10 ± 14.23 86.22 ± 8.17 74.97 ± 14.45 0.31 0.22
Learning problems 65 70.28 ± 15.21 68.90 ± 15.78 72.56 ± 13.03 64.81 ± 14.76 0.17 0.27
Executive function 65 75.34 ± 12.25 73.00 ± 13.69 73.97 ± 10.30 63.56 ± 11.64 0.00b 0.75
Aggression 65 79.83 ± 13.07 73.66 ± 15.18 81.44 ± 13.25 68.39 ± 17.60 0.17 0.32
Peer relations 65 74.48 ± 18.10 72.14 ± 16.06 75.83 ± 14.70 68.89 ± 18.82 0.26 0.18
DSM inattention 65 80.83 ± 9.32 75.97 ± 12.74 80.33 ± 8.08 67.44 ± 13.08 0.01b 0.66
DSM hyperactivity 65 85.90 ± 6.60 77.28 ± 14.59 84.75 ± 9.17 73.00 ± 14.73 0.19 0.29
Conduct disorder 65 74.86 ± 15.71 66.07 ± 14.43 74.17 ± 15.65 62.56 ± 17.16 0.23 0.22
Oppositional defiant disorder 65 79.45 ± 10.67 69.41 ± 18.67 81.22 ± 10.78 67.92 ± 15.51 0.54b 0.09
Global ADHD index 65 85.03 ± 7.70 78.14 ± 13.47 85.25 ± 8.78 71.86 ± 14.01 0.04 0.46
Impaired school life 65 2.17 ± 0.93 1.93 ± 1.07 2.61 ± 0.73 1.75 ± 1.05 0.30 0.17
Impaired relationships 65 1.76 ± 1.09 1.79 ± 0.90 2.11 ± 0.89 1.56 ± 1.08 0.17 0.24
Impaired home life 65 2.21 ± 0.94 1.86 ± 0.74 2.36 ± 0.72 1.58 ± 1.05 0.06b 0.30
ADHD probability 65 93.69 ± 16.71 80.79 ± 29.61 94.89 ± 15.64 72.97 ± 28.58 0.18 0.27
a Significant values—Bonferroni multiple comparison test
b Outcome was associated with a main effect for medication
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ADHD probability scores were associated with main effects
for diagnosis and medication status.
Adverse effects
There was a significant difference between groups in ‘feeling
colder’ at baseline; however, this difference dissipated at the
end of the study. No other differences in symptomswere noted
at baseline or during the course of the study (see Table 9).
Post-treatment follow-up
Week 18 final behaviour (CPRS) and mood (BRUMS)
follow-up compliance completion was low (53%). Paired
sample t test indicated a significant worsening in executive
function for the placebo group in the CT condition
(p = 0.05; d = −0.34). There was a significant increase in
tension (p = 0.05, d = 0.36) throughout the whole sample in
the PCSO-524® group, following cessation of treatment. In
subsample analysis, those children who had been diagnosed
with ADHD and who had finished taking PCSO-524®
showed increased tension (p = 0.05, d = 0.51) and symptoms
of depression (p = 0.02, d = 0.58). These results should be
interpreted with caution due to the low completion rate.
Dropouts, withdrawals and compliance
There were 24 participant dropouts. The majority of drop-
outs occurred due to family issues (n = 9 placebo; PCSO-
524® n = 4) that left the participant unable to complete
testing procedures (see Fig. 1 for a study recruitment
flowchart). A common issue with younger participants
was an inability to swallow the capsules (placebo n = 7;
PCSO-524® n = 4). Some participants began ADHD
medication or made adjustments to their medication reg-
imen (placebo n = 3; PCSO-524® n = 2) and were ex-
cluded from further testing. Two participants withdrew
from the study due to symptoms; one participant
complained of an increase in noise sensitivity (placebo),
and one parent reported an increase in the child’s
Baseline Week 8 Week 14
PCSO-524 83.95 85.87 84.92
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Correct Non-Target Picture Recognion
Fig. 2 Graphs showing accuracy percentage on picture recognition accuracy, accuracy for correct target picture recognition and accuracy for correct
non-target picture recognition
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hyperactivity while at home (PCSO-524®). Two further
participants did not comply with treatment and testing
protocols and were withdrawn from the analysis (PCSO-
524® n = 2). Ten interstate participants were lost to
follow-up and failed to return any data (PCSO-524®
n = 5). Compliance rates were determined via a pill
count, the compliance diary and a follow-up telephone
call. The mean recorded compliance rates with the single
daily intake were 96.67%. There were no significant dif-
ferences between compliance, diagnosis and ADHD med-
ication between the treatment groups.
Discussion
The results of this study did not support the hypothesis
that PCSO-524® would improve parent-rated levels of
hyperactivity, inattention and impulsivity in children with
high levels of behavioural problems aged 6 to 14 years
over placebo. Despite this, several positive findings in
exploratory subgroup analyses revealed specific benefits
of PCSO-524® in ameliorating the symptoms of hyperac-
tivity and inattention in children who did not meet criteria
for parental ratings of combined hyperactivity and inatten-
tion. In addition, those children consuming PCSO-524®
demonstrated significant memory improvements on cog-
nitive tasks against placebo, regardless of symptom sever-
ity. The present study utilised parents’ ratings to under-
stand how the symptoms present in each child affected
their behaviour at home and at school, regardless of their
clinical diagnosis. This type of exploratory subsample
analysis allows researchers to understand the benefits of
unique treatments such as PCSO-524® and has been
utilised previously in rigorous intervention trials in child
and adolescent populations (Manor et al. 2012).
Significant improvements in hyperactivity, inattention and
learning in the NCT group highlight the possibility of mineral
deficiencies in the subsample population under study. This is
consistent with previous research indicating parental ratings of
children’s behaviour correlates with mineral deficiencies
(Sinn et al. 2008) as well as prevalence rates of ADHD
(Visser et al. 2013). This also highlights the possibility for
future dose range investigations of this extract (PCSO-
524®) in order to determine whether children classified as
combined type require a larger dose of the intervention or if
unrelated factors lead to the lack of improvement in behav-
ioural ratings. The Conners Rating Scales are among the most
validated test instruments used in research on ADHD and
subclinical levels of ADHD (Archer and Newsom 2000).
Hurtig et al. (2007) investigated the presence and severity of
ADHD symptoms in a cohort of Finnish children and adoles-
cents in whom ADHD had been diagnosed. Findings indicat-
ed that those children who had a combined subtype diagnosis
had significantly worse problems of inattention, compared
with children who had the inattentive subtype alone. This
may indicate as to why the NCT children in the current trial
benefited more from the treatment intervention than those who
had a CT outcome. Furthermore, children within the NCT
subsample who displayed levels of high inattention only dem-
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Fig. 3 Effects of PCSO-524®
(Lyprinol/Omega-XL) on the
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outcomes. Graphs depict mean
COMPASS reaction time scores
with SD at baseline, week 8 and
week 14 compared to placebo.
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d effect sizes are provided
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children classified as high hyperactivity only or non-subtype.
This outcome supports a previous study by Johnson et al.
(2009) that demonstrated that responders to a combination
of lipids were more likely to be male and have a diagnosis
of ADHD inattentive subtype. Gillies et al. (2012) concluded
that combined omega-3 and omega-6 PUFA supplements may
be more likely to improve ADHD-associated symptoms than
omega-3 supplementation alone. Previous biochemical re-
ports have highlighted that the potent anti-inflammatory prop-
erties of P. canaliculusmay be due to the synergistic action of
multiple PUFAs, rather than the omega-3 (DHA) content by
itself (Treschow et al. 2007).
The significant improvements in whole sample COMPASS
scores on measures of picture recognition indicate that PCSO-
Table 7 Test of Variables of Attention (TOVA) target-infrequent means and standard deviations for non-diagnosed subsample
First half (target infrequent—attention)
Baseline Week 14 p valuea Cohen’s d
n QTR 1 QTR 2 QTR 1 QTR 2
Response time variability
PCSO-524® 38 235.14 ± 97.90 237.69 ± 105.96 203.83 ± 69.07 239.73 ± 90.72 0.19 0.47
Placebo 236.32 ± 89.98 209.14 ± 97.54 287.52 ± 123.32 238.60 ± 86.55
Response time
PCSO-524® 37 632.32 ± 129.48 655.52 ± 123.68 595.83 ± 133.68 687.32 ± 164.01 0.83 0.10
Placebo 632.00 ± 136.38 663.14 ± 160.27 650.35 ± 120.80 648.00 ± 132.14
D′ prime
PCSO-524® 38 2.30 ± 1.73 2.42 ± 1.66 2.00 ± 1.51 2.31 ± 2.10 0.63 0.04
Placebo 2.14 ± 1.38 2.64 ± 1.63 2.27 ± 1.96 2.09 ± 1.88
Correct response
PCSO-524® 38 23.04 ± 10.74 22.77 ± 11.13 24.61 ± 8.49 22.09 ± 9.51 0.96 0.13
Placebo 25.18 ± 8.96 23.57 ± 8.89 23.25 ± 10.28 20.15 ± 10.12
Correct non-response
PCSO-524® 38 106.39 ± 25.85 115.15 ± 15.53 102.65 ± 31.43 109.41 ± 28.31 0.71 0.10
Placebo 109.27 ± 14.52 115.86 ± 12.16 108.10 ± 17.63 108.05 ± 17.85
Errors of omission
PCSO-524® 36 0.33 ± 0.27 0.36 ± 0.31 0.31 ± 0.23 0.39 ± 0.26 0.82 0.02
Placebo 0.30 ± 0.24 0.34 ± 0.25 0.34 ± 0.28 0.39 ± 0.29
Errors of commission
PCSO-524® 36 0.11 ± 0.13 0.07 ± 0.10 0.18 ± 0.24 0.12 ± 0.22 0.46 0.19
Placebo 0.13 ± 0.12 0.07 ± 0.08 0.12 ± 0.11 0.10 ± 0.12
Post commission
PCSO-524® 38 5.11 ± 3.80 4.15 ± 3.56 6.70 ± 5.51 4.95 ± 5.27 0.89 0.01
Placebo 7.86 ± 5.01 4.76 ± 4.10 6.60 ± 3.78 4.95 ± 3.79
Post commission response time
PCSO-524® 38 627.29 ± 252.50 626.23 ± 269.37 555.00 ± 209.43 575.41 ± 265.83 0.16 0.43
Placebo 602.00 ± 126.53 530.95 ± 255.98 705.90 ± 232.93 614.60 ± 221.22
Post commission variability
PCSO-524® 38 179.18 ± 156.39 145.77 ± 137.25 127.13 ± 94.86 157.59 ± 169.81 0.02 0.66
Placebo 200.45 ± 136.85 125.14 ± 131.84 268.30 ± 163.49 201.20 ± 145.11
Anticipatory response
PCSO-524® 37 0.03 ± 0.07 0.02 ± 0.03 0.05 ± 0.13 0.05 ± 0.13 0.55 0.18
Placebo 0.02 ± 0.02 0.01 ± 0.02 0.03 ± 0.06 0.03 ± 0.04
Multiple responses
PCSO-524® 38 3.22 ± 5.56 2.42 ± 4.66 2.65 ± 3.61 2.77 ± 4.54 0.54 0.25
Placebo 1.36 ± 2.48 1.76 ± 3.74 3.90 ± 6.78 4.55 ± 5.96
a Bonferroni multiple comparison test
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524® may improve elements of delayed working memory. In
a study that investigated omega-3 supplementation in young
healthy adults, improvements were seen in terms of memory
and reaction times, which complemented the improved cogni-
tive results reported here (Stonehouse et al. 2013). Cognitive
changes across different intervention studies are often difficult
to compare with different measures often used. A recent
approach to better understand the cognitive domains mea-
sured by different tests has been suggested by Pase and
Stough (2014), who have advocated for the use of the
Cattell-Horn-Carroll (CHC) cognitive framework for in-
terventions. Future studies should use the CHC as a meth-
od to understand which cognitive domains have been test-
ed from study to study.
Table 8 Test of Variables of Attention (TOVA) target-frequent means and standard deviations for non-diagnosed subsample
Second half (target frequent—inhibition)
Baseline Week 14 p valuea Cohen’s d
n QTR 3 QTR 4 QTR 3 QTR 4
Response time variability
PCSO-524® 24 250.55 ± 94.20 262.05 ± 108.14 241.25 ± 57 254.42 ± 85.89 0.30 0.45
Placebo 264.60 ± 122.51 270.56 ± 136.35 283.75 ± 103.90 294.79 ± 100.07
Response time
PCSO-524® 25 547.14 ± 123.16 540.50 ± 161.68 586.48 ± 145.97 589.37 ± 152.46 0.65 0.14
Placebo 541.40 ± 133.95 531.24 ± 150.48 582.00 ± 171.18 551.71 ± 133.53
D′ prime
PCSO-524® 24 1.49 ± 1.18 1.11 ± 0.92 1.76 ± 1.74 1.29 ± 1.62 0.49 0.23
Placebo 1.24 ± 1.21 1.22 ± 1.10 1.24 ± 1.29 1.12 ± 0.97
Correct response
PCSO-524® 25 87.48 ± 34.20 83.10 ± 34.48 78.10 ± 34.93 68.11 ± 35.87 0.56 0.03
Placebo 84.70 ± 35.34 82.18 ± 36.44 72.69 ± 33.95 71.57 ± 33.43
Correct non-response
PCSO-524® 25 23.33 ± 8.60 19.95 ± 8.65 26.52 ± 8.35 26.00 ± 8.75 0.70 0.12
Placebo 21.70 ± 7.00 20.88 ± 7.94 24.69 ± 6.73 25.88 ± 7.82
Errors of omission
PCSO-524® 21 0.27 ± 0.27 0.29 ± 0.27 0.34 ± 0.27 0.41 ± 0.29 0.99 0.03
Placebo 0.28 ± 0.21 0.32 ± 0.26 0.37 ± 0.26 0.36 ± 0.25
Errors of commission
PCSO-524® 21 0.34 ± 0.23 0.41 ± 0.22 0.27 ± 0.22 0.28 ± 0.23 0.63 0.11
Placebo 0.36 ± 0.17 0.37 ± 0.19 0.28 ± 0.17 0.31 ± 0.18
Post commission
PCSO-524® 24 10.29 ± 5.84 11.45 ± 5.32 7.15 ± 4.85 7.22 ± 8.67 0.26 0.30
Placebo 11.00 ± 5.14 10.65 ± 5.43 8.88 ± 4.75 8.43 ± 5.14
Post commission response time
PCSO-524® 24 545.76 ± 146.87 541.00 ± 178.39 587.30 ± 171.72 549.39 ± 190.90 0.99 0.09
Placebo 588.65 ± 220.08 532.76 ± 125.79 638.31 ± 233.62 533.07 ± 185.12
Post commission variability
PCSO-524® 24 189.90 ± 132.14 217.10 ± 132.14 217.35 ± 154.35 267.00 ± 144.74 0.84 0.13
Placebo 235.35 ± 164.26 283.24 ± 145.12 240.38 ± 171.10 203.21 ± 144.98
Anticipatory response
PCSO-524® 24 0.05 ± 0.10 0.07 ± 0.12 0.06 ± 0.14 0.07 ± 0.14 0.86 0.06
Placebo 0.06 ± 0.12 0.09 ± 0.18 0.05 ± 0.06 0.06 ± 0.08
Multiple responses
PCSO-524® 24 3.33 ± 5.35 6.70 ± 6.07 2.90 ± 4.91 4.79 ± 6.17 0.05 0.48
Placebo 5.85 ± 7.13 7.00 ± 7.35 7.19 ± 6.59 6.21 ± 6.42
a Bonferroni multiple comparison test
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In clinical and subclinical domains, externalised symptoms
such as hyperactivity and inattention require accurate mea-
sures by which research can detect changes reliably.
Continuous performance tests (CPTs) offer crucial insight into
issues with inattention and impulsivity. Greenberg and
Waldman (1993) established the normative data for the
TOVA (formerly the Minnesota Computer Assessment;
Greenberg 1987) in a 1993 publication that used data collected
from 775 children aged 6 to 16. In the present study, the results
from the TOVA testing assessed the accuracy and speed at
which participants recovered after they made an error, which
was denoted as post commission. In a consistent trend, chil-
dren without ADHD who consumed PCSO-524® demon-
strated an improved ability to respond faster to targets
consistently following an incorrect response. A previous study
by Vaisman et al. (2008) suggested that interventions with
greater EPA/DHA ratios, even in subgram amounts, could
impact the visual sustained attention performance in paediatric
populations. Despite promising subsample outcomes, whole
sample analysis of the TOVA results did not demonstrate sig-
nificant improvements in either treatment group.
Neurochemical explanations for improvements in hy-
peractivity, impulsivity and inattention remain difficult
to discern. In a study by Ma et al. (2011), researchers
established that children who were classified to have
ADHD hyperactive/impulsive type had significantly lower
cortisol levels than the ADHD combined type and ADHD
inattentive-type children. As PCSO-524® is an effective
mediator for the 5-LOX and 12-LOX pathways, its pres-
ence in this study may have improved levels of cortisol
via its effect on cytokines. Cytokines play a key role in
the hypothalamic-pituitary-adrenal (HPA) axis and have
been shown to be involved in cognitive processes, stress
and depression (Wilson et al. 2002). Lower levels of
omega-3 (DHA) within the adult brain have been shown
to dysregulate the functions of the HPA axis (Vaisman
et al. 2008). Lipid profile studies have demonstrated a
higher AA/EPA ratio in those children with ADHD
(Stonehouse et al. 2013). Improvements in this AA/EPA
status has correlated with a decrease in ADHD-associated
symptoms (Stonehouse et al. 2013). Germano et al. (2007)
evaluated the effects of LC PUFAs in ADHD children
against normal controls highlighting a significant correla-
tion between improved clinical symptoms of hyperactivity
and inattention with reduced disparity in the AA/EPA ra-
tio. Despite the lower level of omega-3s in PCSO-524®,
previous evidence of its ability to block pro-inflammatory
pathways highlights a possible mechanism of action via
returning the AA/EPA ratio or inflammatory/anti-
inflammatory ratio to a more balanced state (Halpern
2000; Lello et al. 2012; Gillies et al. 2012). LC PUFAs
improve blood lipid profiles, cardiovascular health, cell
membrane fluidity and cell signalling cascades, so the
introduction of any amount of LC PUFAs into a cell sys-
tem that has low levels of it may improve behaviours
which are affected by its absence. The most prevalent
fatty acid within the brain is DHA, which constitutes 45
to 65% of fatty acids in nervous tissues (Ma et al. 2011).
There were no significant differences in compliance,
omega-3 intake through food or reporting of symptoms
between treatment groups, and these results may indicate
an increased bioavailability of omega-3s in the brain fol-
lowing PCSO-524® supplementation.
Limitations of the current study include the broad spec-
trum of participants. Despite the large sample size, the
variety in participant demographics, diagnostic status
and locations may hinder the extrapolation of the results.
Table 9 Symptom checklist outcomes at baseline and at week 14
between treatment groups
Symptom Baseline differences Week 14
Change in energy 0.66 0.84
Skin irritation 0.13 0.69
Feel colder 0.01a 0.48
Feeling hotter 0.08 0.14
Feel dizzy 0.19 0.54
Sweating 0.53 0.44
Blurred vision 0.26 0.46
Nauseous 0.63 0.87
Heart rate increased 0.89 0.86
Dry mouth 0.34 0.78
Stomach pains 0.66 0.58
Eye pains 0.50 0.81
Ear pains 0.32 0.60
Change in bowel patterns 0.90 0.62
Bruising 0.12 0.69
Change in breathing 0.73 0.40
Change in hunger 0.34 0.94









Sleep patterns 0.07 1.00
Tremors 0.13 0.06b
a Significant baseline difference in symptoms of feeling colder which
disappeared at study’s end
b Trending significance for feelings of tremors with reductions in the
PCSO-524® group and increases in the placebo group
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Although it does not directly impact the outcome of the
data collected, the small number of participants’ families
who failed to provide medication information diminishes
any inferences that could be made regarding medication-
specific adjunct treatment. The significant number of the
males in the study may highlight a well-known bias in the
wider population; males with ADHD tend to exhibit more
externalising behaviours such as hyperactivity, inattention
and impulsivity, whereas females with ADHD tend to ex-
hibit more social issues and internalising comorbidities
(anxiety) (Gershon and Gershon 2002; Carlson et al.
1997). This bias may impact the reasons parents decide
to join the study as well as explain the greater number of
males over females recruited. The outcome of the male-
only analysis indicates that PCSO-524® may be benefi-
cial for young males with issues of hyperactivity or inat-
tention at the subclinical level. Further investigations need
to be done to verify this outcome.
Conclusions
The primary outcome of the current study was not sup-
ported by the results. Replicated randomised trials with
dose variations and lipid profiling are needed to under-
stand the neurological and behavioural benefits of
PCSO-524® in this population. Despite this, exploratory
post hoc analysis of the primary outcome of the current
study indicates promise for the use of PCSO-524® in
the treatment of symptoms of inattention, hyperactivity
and impulsivity in children and adolescents with or
without ADHD displaying less severe behavioural
symptoms. PCSO-524® also indicated an ability to im-
prove working memory in children and adolescents with
increased levels of hyperactivity, inattention and impul-
sivity. Post hoc analysis of those children with a diag-
nosis of ADHD also demonstrated improved inhibition
and reduced error making compared to placebo. The use
of PCSO-524® as an adjunctive treatment should be
subjected to additional clinical trials (i.e. together with
stimulant medication). Further large-scale RCTs should
be conducted administering PCSO-524® to children and
adolescents with subclinical levels of hyperactivity inat-
tention and impulsivity. Future neuroimaging trials may
assist in elucidating the mechanism of action.
Clinical significance
PCSO-524®, a marine-based LC PUFA, may be a safe alter-
native to standard pharmaceutical treatments for children and
adolescents with ADHD who have less severe levels of hy-
peractivity, inattention and impulsivity.
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